This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

New Serological Markers for Eosinophilic Esophagitis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2011 by Technische Universität München.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Technische Universität München Identifier:
First received: February 8, 2011
Last updated: June 16, 2012
Last verified: February 2011
The purpose of the study is to investigate if serological parameters such as "extracellular Serum-Tryptase (ST)" and "eosinophilic cationic protein (ECP)" are useful for the diagnosis and surveillance of the eosinophilic esophagitis (EE).

Condition Intervention
Eosinophilic Esophagitis Drug: Fluticasone

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Technische Universität München:

Estimated Enrollment: 20
Study Start Date: January 2011
Groups/Cohorts Assigned Interventions
eosinophilic esophagitis
patients with histopathological defined eosinophilic esophagitis
Drug: Fluticasone
Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings

Detailed Description:

The eosinophilic esophagitis (EE) is chronic inflammatory and immunological disease. The diagnosis of EE is based upon large numbers of eosinophils in the esophagus on histopathologic examination (> 20 eosinophils per high powered field in at least one specimen) despite acid suppression with a Proton-Pump-Inhibitor (PPI) for at least two weeks.

There are no diagnostic serological markers for EE so far, so that the purpose of the study is to investigate serological markers which are established in other allergic diseases.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
primary care clinic

Inclusion Criteria:

  • histopathological defined eosinophilic esophagitis
  • Age: 18-80

Exclusion Criteria:

  • missing consent form
  • contraindications for performing esophagogastroscopy/taking biopsies of the esophagus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01624129

Contact: Monther Bajbouj, MD +49-89-41402450
Contact: Christoph Schlag, MD +49-89-41402450

II. Medical Department, Technical University Munich Recruiting
Munich, Bavaria, Germany, 81675
Contact: Monther Bajbouj, MD    0049-89-41400   
Sponsors and Collaborators
Technische Universität München
Principal Investigator: Monther Bajbouj, MD Technical University of Munich, 2nd Medical Department
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Technische Universität München Identifier: NCT01624129     History of Changes
Other Study ID Numbers: 2011_0023
Study First Received: February 8, 2011
Last Updated: June 16, 2012

Additional relevant MeSH terms:
Eosinophilic Esophagitis
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Leukocyte Disorders
Hematologic Diseases
Hypersensitivity, Immediate
Immune System Diseases
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents processed this record on September 21, 2017